Affymax revealed the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company, effective September 10, 2014. Under a previous agreement, Affymax and Takeda voluntarily recalled all lots of Omontys and suspended promotional activities in the US upon postmarketing reports of serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal. Based on the postmarketing reports and related discussions with Takeda, Affymax has elected not to exercise its rights with respect to the Omontys New Drug Application.